Methods and compositions for the treatment of vascular anomalies

By employing famesyltransferase and geranylgeranyltransferase inhibitors in combination with other therapeutic agents, the treatment of vascular anomalies like infantile hemangioma can be enhanced, achieving effective inhibition of vessel formation while minimizing adverse effects.

WO2025101692A1 Publication Date: 2025-05-15CHILDRENS MEDICAL CENT CORP
3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/054845
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-10
Filing Date
2024-11-07
Publication Date
2025-05-15

AI Technical Summary

Technical Problem

Current treatments for vascular anomalies, such as infantile hemangioma, often come with significant adverse effects and not all tumors respond to existing therapies, highlighting the need for more effective and safer treatments.

Method used

The use of famesyltransferase and geranylgeranyltransferase inhibitors, either alone or in combination with statins, beta-blockers, mTOR inhibitors, and steroids, to target the differentiation pathways of hemangioma-derived stem cells, thereby inhibiting vessel formation in vascular anomalies.

Benefits of technology

This approach effectively reduces vessel density and inhibits blood vessel formation in murine xenograft models of infantile hemangioma, demonstrating potential therapeutic efficacy in treating vascular anomalies with reduced side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The technology described herein is directed to methods and compositions relating to the treatment of vascaular anomalies, e.g. hemangiomas, including the discovery that famesyltransferase and / or geranylgeranyltransferas inhibitors target pathways controlling the differentiation of hemangioma-derived stem cells.
Need to check novelty before this filing date? Find Prior Art